Meckler Jeffrey A — SEC insider filings
SEC reporting owner CIK 1506916. 26 insider filings on record with FilingPulse; latest filed 2026-09-11.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2021-05-18 to 2026-09-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 6 filings — 72,914 shares, $273,569 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 3 filings — 68,000 shares, $2,268,430 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 44.
- Largest priced transaction: sale of 14,000 shares @ $67.46 ($944,488) in Travere Therapeutics, Inc., filed 2026-09-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Director | 9 | — | 6 legs · 68,000 sh · $2,268,430 | 20 |
| Indaptus Therapeutics, Inc. (INDP) | Co-Chief Executive Officer, Director | 17 | 8 legs · 72,914 sh · $273,569 | — | 24 |
Insider filings — Meckler Jeffrey A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $17.44 · Option exercise (M): 10,000 @ $26.52 · Sale (S): 1,700 @ $65.39 · Sale (S): 1,200 @ $66.15 · Sale (S): 14,000 @ $67.46 · Sale (S): 3,100 @ $68.09 · +2 more | EDGAR |
| 2026-05-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 @ $16.33 · Sale (S): 8,000 @ $45 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Indaptus Therapeutics, Inc. (INDP) | Disposition to issuer (D): 3,033 (derivative) · Grant/award (A): 3,033 (derivative) · Disposition to issuer (D): 1,519 (derivative) · Grant/award (A): 1,519 (derivative) · Disposition to issuer (D): 12,136 (derivative) · Grant/award (A): 12,136 (derivative) | EDGAR |
| 2025-12-29 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 216,617 @ $2.03 | EDGAR |
| 2025-07-29 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 6,068 @ $8.30 · Grant/award (A): 12,136 (derivative) @ $8.30 | EDGAR |
| 2025-05-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Indaptus Therapeutics, Inc. (INDP) | Disposition to issuer (D): 4,750 (derivative) @ $0.04 · Disposition to issuer (D): 3,750 (derivative) @ $0.04 · Disposition to issuer (D): 813 (derivative) @ $0.04 · Disposition to issuer (D): 1,500 (derivative) @ $0.04 · Disposition to issuer (D): 1,563 (derivative) @ $0.04 · Disposition to issuer (D): 1,250 (derivative) @ $0.04 | EDGAR |
| 2024-11-26 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 42,553 @ $1.18 · Grant/award (A): 42,553 (derivative) @ $1.18 | EDGAR |
| 2024-10-10 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 40,000 @ $10.48 · Sale (S): 40,000 @ $14.06 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-08-08 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 84,932 @ $1.82 · Grant/award (A): 84,932 (derivative) @ $1.82 | EDGAR |
| 2024-05-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,500 @ $0 · Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-11-22 | 4 | Indaptus Therapeutics, Inc. (INDP) | Purchase (P): 400 @ $1.76 · Purchase (P): 9,600 @ $1.90 | EDGAR |
| 2022-09-12 | 4 | Indaptus Therapeutics, Inc. (INDP) | Purchase (P): 10,308 @ $2.80 | EDGAR |
| 2022-09-08 | 4 | Indaptus Therapeutics, Inc. (INDP) | Purchase (P): 1,060 @ $2.44 · Purchase (P): 8,632 @ $2.57 | EDGAR |
| 2022-06-07 | 4 | Indaptus Therapeutics, Inc. (INDP) | Purchase (P): 19,727 @ $2.63 | EDGAR |
| 2022-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 3,000 @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2022-01-28 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Indaptus Therapeutics, Inc. (INDP) | Purchase (P): 11,187 @ $5.82 | EDGAR |
| 2021-09-16 | 4 | Indaptus Therapeutics, Inc. (INDP) | Purchase (P): 12,000 @ $7 | EDGAR |
| 2021-08-06 | 4 | Indaptus Therapeutics, Inc. (INDP) | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 3,000 @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-05-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1506916 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs